NCT01902225View on ClinicalTrials.gov

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 4, 2014

Primary Completion Date

July 13, 2018

Study Completion Date

April 11, 2020

Conditions
LymphomaT-Cell LymphomaCutaneous Lymphoma
Interventions
DRUG

Istodax

DRUG

Doxil

Trial Locations (2)

43210

Ohio State University Comprehensive Cancer Center, Columbus

94115

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Weiyun Ai

OTHER

NCT01902225 - Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma | Biotech Hunter | Biotech Hunter